Nine million people enrolled in Medicare entered 2026 paying less for some of the most widely prescribed drugs in the United States. Negotiated Maximum Fair Prices for the first 10 Part D drugs took effect on January 1, 2026, after the Centers for Medicare and Medicaid Services completed the inaugural round of price negotiations authorized by the Inflation Reduction Act. Those beneficiaries paid a combined $3.4 billion out of pocket for these same medications in 2022, and CMS projects aggregate out-of-pocket savings of $1.5 billion for 2026 alone.
How negotiated prices change what seniors pay in 2026
The 10 drugs selected for the first negotiation cycle treat conditions that affect millions of older Americans, including diabetes, heart disease, and blood clots. CMS published the negotiated prices for the initial applicability year in a fact sheet that lists each drug’s Maximum Fair Price alongside its prior list price. An ASPE issue brief comparing those MFPs to list prices and typical U.S. market transaction prices confirms that the new figures fall well below what pharmacies and insurers previously paid, supporting the claim that individual out-of-pocket costs could drop by more than half for many beneficiaries.
The savings are not evenly distributed. Seniors who lack supplemental coverage or who fall into higher cost-sharing tiers stand to benefit most, because their copays and coinsurance are calculated as a percentage of the drug’s price. When that price drops sharply, so does the dollar amount owed at the pharmacy counter. CMS has posted drug-by-drug files with NDC-level pricing data so that plan sponsors, pharmacists, and beneficiaries can verify the exact new cost for a 30-day supply of each medication.
For individual patients, the change shows up in several ways. Some will see lower flat copays because their plan’s cost-sharing tiers are recalibrated when underlying prices fall. Others, especially those facing coinsurance, will notice that the percentage they pay is applied to a smaller base amount, cutting their bill even if the nominal coinsurance rate stays the same. And for beneficiaries who previously hit the catastrophic phase of Part D coverage, lower prices can slow the pace at which they accumulate spending, potentially keeping them in lower-cost phases longer during the year.
These reductions interact with other Inflation Reduction Act provisions, such as annual caps on Part D out-of-pocket spending, amplifying the effect for people with multiple high-cost prescriptions. While CMS’s headline estimate focuses on the 10 negotiated drugs, the combined impact of negotiation, caps, and limits on price growth is expected to reshape what many seniors budget for medicines in 2026.
Whether lower prices could drive higher volume and offset projected savings
A reasonable question is whether cutting per-unit prices will simply increase the number of prescriptions filled, pushing total Medicare spending back up. The logic runs like this: lower copays reduce the financial barrier that causes some patients to skip doses or abandon prescriptions entirely. If adherence rises enough, the program could end up covering more total units than it did before negotiation, and the net savings could shrink or even reverse within a few years.
Available evidence does not yet confirm or rule out that outcome. CMS’s $1.5 billion savings estimate for 2026, cited in its press release on the negotiation program, reflects aggregate out-of-pocket reductions, not total program expenditure. No primary CMS or ASPE file published so far supplies beneficiary-level claims data showing actual 2026 prescription volumes after MFP implementation. The $3.4 billion baseline from 2022 captures what patients paid, but it does not project how many additional fills lower prices might generate.
Improved medication adherence generally reduces downstream hospitalizations and emergency visits, which could produce offsetting savings elsewhere in the Medicare budget. For example, better control of diabetes and cardiovascular conditions can avert complications that are far more expensive than the drugs themselves. In that scenario, Medicare might spend slightly more on prescriptions while saving more on inpatient and acute care, yielding net savings that do not appear in drug-spending figures alone.
At the same time, policymakers and analysts caution against assuming that every additional prescription is purely beneficial. Some portion of higher volume could reflect earlier or more aggressive use of expensive therapies when lower-cost alternatives remain appropriate. Without detailed utilization and outcomes data, it is not yet possible to separate cost-increasing overuse from cost-saving improvements in adherence.
For now, the clearest, documented effect of the first negotiation round is the immediate relief for beneficiaries who rely on the 10 targeted drugs. The Maximum Fair Prices reset what many seniors pay at the pharmacy counter, and CMS’s published estimates frame 2026 as the first year in which those negotiated discounts translate into billions of dollars in out-of-pocket savings. Whether higher utilization meaningfully erodes those gains-or is offset by better health and lower medical spending elsewhere-will only become clear as Medicare releases more comprehensive data on how patients and prescribers respond to the new prices.
